[EN] USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION<br/>[FR] UTILISATION D'UN INHIBITEUR DE GSK-3 BETA DANS LA FABRICATION D'UN MEDICAMENT POUR ACCROITRE LA FORMATION OSSEUSE
申请人:HOFFMANN LA ROCHE
公开号:WO2003057202A1
公开(公告)日:2003-07-17
This invention relates to the use of inhibitors of glycogen synthase kinase-3β to increase bone formation.
Here we report on the discovery of a series of maleimides which have high potency and good selectivity for GSK-3 beta. The incorporation of polar groups afforded compounds with good bioavailability. The most potent compound 34 has an IC(50) of 0.6 nM for GSK-3 beta, over 100-fold selectivity against a panel of other kinases, and shows efficacy in rat osteoporosis models. The X-ray structure of GSK-3 beta protein with 34 bound revealed the binding mode of the template and provided insights for future optimization opportunities. (C) 2010 Elsevier Ltd. All rights reserved.
3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA
申请人:F. Hoffmann-La Roche AG
公开号:EP1307447B1
公开(公告)日:2004-12-15
USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION